-+ 0.00%
-+ 0.00%
-+ 0.00%

Altimmune Announces Public Offering; Quantity And Termination Date Not Disclosed

Benzinga·04/22/2026 20:26:11
Listen to the news

Altimmune intends to use the net proceeds from this proposed offering to fund its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), as well as for working capital and general corporate purposes.